1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 1,650 | 1,802 | 03.01. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| MABION Aktie jetzt für 0€ handeln |
0 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 82,45 | -0,06 % | BYD gegen Tesla! KI-Profiteure BioNTech und Rio Tinto Partner Aspermont! Aktien für 2026? | Paukenschlag kurz vor Silvester! BYD hat Tesla vom E-Auto-Thron gestoßen. Die Chinesen sind jetzt auch Weltmarktführer bei rein elektrischen Fahrzeugen. Doch die Aktie hat 2025 klar enttäuscht. Ein... ► Artikel lesen | |
| CUREVAC | 3,878 | +7,13 % | Morgen-Update: Curevac-Aktie stabil - Marktbeobachter rechnen mit Bewegung. | ||
| MODERNA | 26,345 | 0,00 % | Forget Moderna Stock, This is a Much Better Buy | ||
| STRYKER | 298,00 | +0,27 % | Dividendenbekanntmachungen (31.12.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACADIA REALTY TRUST US0042391096 0,2 USD 0,1702 EUR ACADIAN TIMBER CORP CA0042721005 0,29 CAD 0,1802 EUR AGNC INVESTMENT CORP US00123Q1040 0... ► Artikel lesen | |
| NOVONESIS | 53,26 | -0,08 % | Novonesis (Novozymes A/S): Novonesis delivered 8% organic sales growth in the first nine months of 2025 | Novonesis delivered 8% organic sales growth in the first nine months of 2025 and narrowed full-year outlook upwards. COPENHAGEN, Denmark - November 6, 2025. Novonesis delivered 8% organic sales growth... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,439 | -0,68 % | Defence Therapeutics Inc.: Defence Therapeutics Announces AGM Results and Provides Corporate Updates | Montreal, Quebec--(Newsfile Corp. - December 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a biotechnology company advancing a proprietary... ► Artikel lesen | |
| VIVORYON THERAPEUTICS | 1,468 | +0,96 % | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates | Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates
New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,391 | -3,69 % | NurExone rückt mit ExoPTEN in den Kreis international anerkannter Biotech-Innovatoren | ||
| HALOZYME THERAPEUTICS | 59,28 | -1,20 % | Halozyme Therapeutics, Inc.: U.S. FDA Approves RYBREVANT FASPRO (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer | RYBREVANT FASPRO is approved across all indications of RYBREVANT® (amivantamab-vmjw)
SAN DIEGO, Dec. 18, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ:... ► Artikel lesen | |
| XOMA ROYALTY | 22,000 | +2,80 % | XOMA Royalty Corporation: XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab | - Takeda regains a majority of XOMA Royalty's royalty interest in mezagitamab (TAK-079) -- XOMA Royalty will be entitled to payments based on a share of milestones and royalties associated with nine... ► Artikel lesen | |
| AFFIMED | 0,972 | 0,00 % | NSE - Affimed N.V. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| TME PHARMA | 0,064 | +0,95 % | TME Pharma announces receipt of agreements in principle to extend certain bond agreements | TME Pharma announces receipt of agreements in principle to extend certain bond agreements Berlin, Germany, November 17, 2025, 08.00am CET - TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage... ► Artikel lesen | |
| CYTODYN | 0,240 | 0,00 % | CytoDyn Inc.: December 2025 Letter to Shareholders | VANCOUVER, Washington, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Dear Shareholders, As we close out the year and step with confidence and purpose into 2026, I want to extend my sincere appreciation for your... ► Artikel lesen | |
| CANSINO BIOLOGICS | 3,720 | -3,38 % | CanSino Biologics Inc: Innovative Vaccine Engine Continues to Drive Growth: CanSinoBIO Enters a New Growth Cycle | HONG KONG, Aug 20, 2025 - (ACN Newswire) - In the first half of 2025, the structural transformation of the pharmaceutical industry continued to deepen. Driven by favorable policies, product upgrades... ► Artikel lesen | |
| NOVOCURE | 11,240 | +0,49 % | Novocure to Present at 44th Annual J.P. Morgan Healthcare Conference | Novocure (NASDAQ: NVCR) announced today that management will participate in the 44th Annual J.P. Morgan Healthcare Conference taking place in San Francisco on January 12-15, 2026. Frank Leonard, Chief... ► Artikel lesen |
MABION SA gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 1,620 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MABION SA finden Sie auf Wallstreet Online.